Merck KGaA (BMV:MRK1 N) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

MRK1 N Overzicht aandelen

Operates as a science and technology company in Germany.

MRK1 N fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	2/6
Prestaties in het verleden	2/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Verhandeld tegen 22.8% onder onze schatting van de reële waarde

De winst zal naar verwachting met 11.95% per jaar groeien

Risicoanalyse

Aandelen zijn zeer illiquide

Merck KGaA Concurrenten

Genomma Lab Internacional. de

BMV:LAB B

Mex$23.6b

Zoetis

NYSE:ZTS

US$86.5b

GSK

LSE:GSK

UK£60.2b

Chugai Pharmaceutical

TSE:4519

JP¥11.6t

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Merck KGaA
Historische aandelenkoersen
Huidige aandelenkoers	€3,179.33
52 Week Hoogtepunt	€3,179.33
52 Week Laag	€2,878.21
Bèta	0.70
11 maand verandering	0%
3 maanden verandering	n/a
1 Jaar Verandering	n/a
33 jaar verandering	-34.75%
5 jaar verandering	n/a
Verandering sinds IPO	-5.93%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	MRK1 N	MX Pharmaceuticals	MX Markt
7D	0%	-1.1%	1.0%
1Y	n/a	-6.3%	9.1%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe MRK1 N presteerde ten opzichte van de MX Pharmaceuticals.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe MRK1 N presteerde ten opzichte van de MX markt.

Prijsvolatiliteit

Is MRK1 N's price volatile compared to industry and market?
MRK1 N volatility
MRK1 N Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.8%
Market Average Movement	4.1%
10% most volatile stocks in MX Market	6.3%
10% least volatile stocks in MX Market	2.9%

Stabiele aandelenkoers: MRK1 N heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van MRK1 N in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1668	62,176	Belen Garijo Lopez	www.merckgroup.com/en

Merck KGaA Samenvatting

Hoe verhouden de winst en inkomsten van Merck KGaA zich tot de beurswaarde?
MRK1 N fundamentele statistieken
Marktkapitalisatie	Mex$1.66t
Inkomsten(TTM)	Mex$57.15b
Inkomsten(TTM)	Mex$454.18b

29.1x

Koers/Winstverhouding

3.7x

P/S-verhouding

Is MRK1 N overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
MRK1 N resultatenrekening (TTM)
Inkomsten	€20.87b
Kosten van inkomsten	€8.68b
Brutowinst	€12.19b
Overige uitgaven	€9.57b
Inkomsten	€2.63b

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

Nov 14, 2024

Winst per aandeel (EPS)	6.04
Brutomarge	58.42%
Nettowinstmarge	12.58%
Schuld/Eigen Vermogen Verhouding	35.3%

Hoe presteerde MRK1 N op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

1.3%

Huidig dividendrendement

36%

Uitbetalingsratio

MRK1 N Overzicht aandelen

Beloningen

Risicoanalyse

Merck KGaA Concurrenten

BMV:LAB B

Mex$23.6b

NYSE:ZTS

US$86.5b

LSE:GSK

UK£60.2b

TSE:4519

JP¥11.6t

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Merck KGaA Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer

Merck KGaA Provides Updates on the Oncology Pipeline and Focused Approach to the Research and Development of Potential New Medicines Designed to Improve the Futures of Cancer Treatment

Merck KGaA, Annual General Meeting, Apr 25, 2025

Recent updates

Merck KGaA Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer

Merck KGaA Provides Updates on the Oncology Pipeline and Focused Approach to the Research and Development of Potential New Medicines Designed to Improve the Futures of Cancer Treatment

Merck KGaA, Annual General Meeting, Apr 25, 2025

Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer

Full year 2023 earnings released: EPS: €6.49 (vs €7.65 in FY 2022)

Merck Kgaa, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis

Merck Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis

Merck KGaA to Report Q4, 2023 Results on Mar 07, 2024

Merck Receives Positive EU CHMP Opinion for PREVYMIS for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease

Merck KGaA, Annual General Meeting, Apr 26, 2024

Merck Announces CFO Changes

Merck Reportedly to Put Pigments Unit Up for Sale Again

MERCK Kommanditgesellschaft auf Aktien to Report Q4, 2022 Results on Mar 02, 2023

MERCK Kommanditgesellschaft auf Aktien Provides Earnings Guidance for the Full Year 2022

Gerresheimer and Merck Transform Primary Packaging into Digital Twins

Upcoming dividend of €1.85 per share

Now 21% undervalued after recent price drop

Now 22% undervalued

Full year 2021 earnings: Revenues in line with analyst expectations

MERCK Kommanditgesellschaft auf Aktien to Report Nine Months, 2022 Results on Nov 10, 2022

Third quarter 2021 earnings released

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Merck Launches New, High-Purity Synthetic Cholesterol Product

First quarter 2021 earnings released

Merck KGaA Provides Earnings Guidance for the First Quarter and Full Year of 2021

Merck KGaA Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer

Genome and Company Signs Second Clinical Trial Collaboration and Supply Agreement (Phase 2) with Merck Kgaa, Darmstadt, Germany and Pfizer for Immuno-Oncology Microbiome Study

Full year 2020 earnings released: EPS €4.57 (vs €2.97 in FY 2019)

Revenue beats expectations

Merck Enters into Multiple Agreements to Support Efforts to Expand Manufacturing Capacity and Supply of SARS-CoV-2/COVID-19 Medicines and Vaccines

Merck and GPHL Collaborate on Business Innovation and Development in the Greater Bay Area

Day One Biopharmaceuticals Announces Global License Agreement with Merck KGaA, Darmstadt, Germany to Develop and Commercialize Mek Inhibitor Pimasertib

MERCK Kommanditgesellschaft auf Aktien to Report Q3, 2021 Results on Nov 11, 2021

4D Pharma plc Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate MRx0518 in Combination with Bavencio for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

Merck KGaA, Darmstadt, Germany, Announces Management Changes for North America and Global Innovative Medicine Franchises in Healthcare

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Merck KGaA Samenvatting

29.1x

3.7x

Inkomsten en omzet

Dividenden

1.3%

36%